Abstract
Background and Aims The efficacy of statin therapy is hindered by adverse drug reactions, most frequently musculoskeletal symptoms. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentration of the drug and its metabolites. While pharmacogenetic testing of the loss-of-function Val174Ala (rs4149056T>C) is recommended to reduce risk of statin intolerance, current guidelines acknowledge the potential role of gain-of-function variants. This study tests the hypothesis that accounting for gain-of-function variants in SLCO1B1, in addition to Val174Ala, will provide more reliable estimates of statin intolerance.
Methods and Results High-risk haplotypes were derived from Val174Ala and three common gain-of-function SLCO1B1 variants and compared to low-risk haplotypes. In statin users from Tayside Scotland, UK, those with high-risk haplotypes had increased odds across three phenotypes of statin intolerance (general statin intolerance: ORGSI 2.42[95%CI:1.29, 4.31], p=0.003; statin-related myopathy ORSRM 2.51[95%CI:1.28, 4.53],p=0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85[95%CI:1.03, 6.65],p=0.02). In contrast, using the Val174Ala genotype alone produced weaker results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99 [95%CI:1.01, 3.95],p=0.048; ORrisk-haplotypes 1.76 [95%CI:1.16, 2.69],p=0.008). For those requiring high-dose statin therapy, high-risk haplotypes were more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared to Val174Ala (general statin intolerance: HRVal174Ala 2.49 [95%CI:1.09, 5.68],p=0.03; HRrisk-haplotypes 2.44 [95%CI:1.46, 4.08],p<0.001). Exome-sequenced rare variants were found to be associated with the risk of intolerance (p=0.02).
Conclusions We demonstrate that accounting for gain-of-function variants in SLCO1B1, in addition to Val174Ala, provides more reliable estimates of statin intolerance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly funded by the National Institute for Health Research (NIHR) (INSPIRED 16/136/102) using aid from the UK government to support global health research. GoDARTS was funded and supported by the Wellcome Trust (Award 072960 and 084726) and the UK Medical Research Council (Award G0601261). SHARE is NHS Scotland Research (NRS) infrastructure initiative and it was funded by the Chief Scientists Office of the Scottish Government. Additional Funding and initiation of the spare blood retention at NHS Tayside was supported by the Wellcome Trust Biomedical Resource (award number 099177/Z/12/Z). PREDICTION-ADR has received funding form the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant Agreement no. 602108. The UK Biobank was primarily funded by the Wellcome Trust and the Medical Research Council. Approval for the study and permission to access the data was granted by the UK Biobank Resource under Application Number 20405.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GoDARTS and SHARE studies were reviewed and approved by Tayside Medical Ethics Committee 053/04 and East of Scotland Ethics committee NHS REC 13/ES/0020. Multiple EU Research Ethics Committees (Tayside, Scotland; North West England, UK: Sefton, UK) gave ethical approval for the PREDICTION-ADR study. UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval, REC reference: 21/NW/0157, IRAS project ID: 299116.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GoDARTS and SHARE data are available subject to approval by the Tayside data access committee and can be made by contacting the corresponding authors. PREDICTION-ADR data are available subject to approval and can be made by contacting the corresponding authors. UK Biobank data are available via application directly to the UK Biobank, https://www.ukbiobank.ac.uk
